Chronic kidney disease (CKD) is a growing public health epidemic that is an established risk factor for cardiovascular morbidity and mortality. An emerging body of evidence suggests that, in addition to traditional risk factors, a number of "uremic" factors contribute to the high prevalence of cardiovascular disease in this population. Left ventricular hypertrophy is a common manifestation of cardiovascular disease in CKD that is associated with increased risk of mortality. Fibroblast growth factor 23, a novel phosphate-regulating hormone that is markedly elevated in patients with CKD, is independently associated with mortality among patients initiating hemodialysis. In the present cross-sectional study of 162 subjects with predialysis CKD and 58 subjects with preserved kidney function, increased fibroblast growth factor 23 concentrations were associated with increased left ventricular mass index and left ventricular hypertrophy independently of known risk factors in CKD such as age, diabetes mellitus, and hypertension. Given that circulating fibroblast growth factor 23 concentrations are elevated early in the course of kidney failure and that fibroblast growth factors have been implicated in the development of myocardial hypertrophy, this study suggests a novel biological mechanism that may contribute to the accelerated development of myocardial disease in CKD. In addition, given that fibroblast growth factor 23 can be lowered with routine clinical interventions that restrict dietary phosphorus absorption, these results may suggest novel therapeutic strategies for ameliorating the development of left ventricular hypertrophy in millions of patients with CKD. See p 2545.
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Effect on Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Clopidogrel has been shown to reduce cardiovascular events in acute coronary syndrome patients. However, interpatient variability in the response to clopidogrel is well recognized, and individuals with lesser degrees of platelet inhibition are at increased risk of death and ischemic complications. Prasugrel is a newer, third-generation thienopyridine that achieves greater platelet inhibition than clopidogrel with less variability. Clopidogrel and prasugrel are prodrugs and require biotransformation to an active metabolite by cytochrome P450 (CYP) enzymes, although the exact activation pathways differ between the 2 drugs. Among persons treated with clopidogrel, carriers of reduced-function CYP2C19 genetic variants (Ϸ30% of the population) have been shown to have significantly lower levels of active drug metabolite, diminished platelet inhibition, and higher rates of adverse cardiovascular events. In this study, we examined the associations between functional variants in CYP genes (CYP2C19, CYP2C9, CYP2B6, CYP3A5, and CYP1A2) and the pharmacological response to prasugrel in 238 healthy subjects and the association of these genetic variants with cardiovascular outcomes (cardiovascular death, myocardial infarction, or stroke) in a cohort of 1466 patients with acute coronary syndrome allocated to treatment with prasugrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 trial. No difference was found in the active drug metabolite levels, platelet inhibition, and rates of adverse cardiovascular events in carriers versus noncarriers of at least 1 reduced-function allele for any of the CYP genes tested. These pharmacogenetic findings with prasugrel are in contrast to observations with clopidogrel, which may explain, in part, the different pharmacological and clinical responses to the 2 medications. See p 2553.
Cardiac Microvascular Pathology in Fabry Disease: Evaluation of Endomyocardial Biopsies Before and After Enzyme Replacement Therapy
Among the many differential diagnoses for ischemic heart disease is one on the lower end of the list: cardiac involvement by Fabry disease, a rare lysosomal disorder resulting from a genetic deficiency of ␣-galactosidase A. This deficiency leads to accumulation of globotriaosylceramide within vascular endothelial cells and cardiomyocytes, resulting in angina, myocardial infarction, and left ventricular hypertrophy, thus mimicking more common diagnoses such as hyperlipidemia and hypertrophic cardiomyopathy. The present study uses endomyocardial biopsies to examine the effectiveness of a new enzyme replacement therapy for Fabry disease on its ability to clear globotriaosylceramide from the cardiac microcirculation. In clinical cases in which a diagnostic cardiac biopsy is sought, it is important that Fabry disease be considered in the differential diagnoses of both the ordering physician and the examining pathologist, so that the biopsy specimen can be optimally fixed and processed for light and electron microscopy to enable confirmation of all possible diagnoses. With the current availability of enzyme replacement therapy for Fabry disease, a correct diagnosis will ensure that patients are treated in a timely manner to alleviate symptoms and to prevent further disease progression. See p 2561.
Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase
Metformin is widely used as an antidiabetic drug with an insulinsensitizing effect. A large-scale clinical trial (the UK Prospective Diabetes Study [UKPDS] 34) has shown that metformin therapy decreased the risk of cardiovascular death and the incidence of myocardial infarction associated with diabetes mellitus; metformin reduced the hemoglobin A 1c levels in treated patients to the same extent as in the other patients treated with conventional therapies. These results suggest that metformin might exert cardioprotective effects beyond its glucose-lowering action such as either activation of AMP-activated protein kinase (AMPK) or elevation of nitric oxide. Metformin is known to activate AMPK, which mediates potent cardioprotection against ischemia/reperfusion injury. AMPK also is activated in experimental failing myocardium, suggesting that activation of AMPK is beneficial for the pathophysiology of heart failure. The present study demonstrated that long-term oral administration of metformin prevents the progression of heart failure as indicated by hemodynamic and echocardiographic parameters. Metformin also promoted phosphorylation of both AMPK and endothelial nitric oxide synthase, increased plasma nitric oxide levels, and improved insulin resistance. As a result of these effects, metformin decreased apoptosis and improved cardiac function in failing canine hearts. Interestingly, another AMPK activator (AICAR) had effects equivalent to those of metformin, suggesting the primary role of AMPK activation in reducing apoptosis and preventing heart failure. Drugs that activate AMPK, especially metformin, may provide a novel strategy for the treatment of heart failure in clinical settings. See p 2568.
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Determinants of Left Ventricular Early-Diastolic Lengthening Velocity: Independent Contributions From Left Ventricular Relaxation, Restoring Forces, and Lengthening Load
Measurement of left ventricular early-diastolic lengthening velocity (eЈ) by tissue Doppler echocardiography is used clinically to evaluate diastolic function, and the ratio between peak transmitral early-diastolic velocity and eЈ has been introduced as a noninvasive estimate of left ventricular diastolic pressure. A number of studies indicate that eЈ is closely related to the rate of left ventricular relaxation. The present experimental study indicates that left ventricular transmural pressure at the onset of diastolic filling, which represents a lengthening load (early-diastolic load), is another important independent determinant of eЈ. Clinically, lengthening load would approximate left ventricular end-diastolic pressure. The present study also indicates that restoring forces, analogous to the elastic recoil after release of a compressed spring, is another important independent determinant of eЈ. Experimentally, restoring forces were quantified as the magnitude of contraction below myocardial resting length. Clinically, this is reflected in end-systolic length and magnitude of contraction. The present study confirmed that rate of relaxation is an independent determinant of eЈ. In the normal heart, with rapid relaxation, lengthening load and restoring forces are probably the main determinants of early-diastolic lengthening velocity. The relative contribution of the different determinants may depend on the functional state of the ventricle, with a more important contribution from rate of relaxation during heart failure. See p 2578.
Sca-1 ؉ Stem Cell Survival and Engraftment in the Infarcted Heart: Dual Role for Preconditioning-Induced Connexin-43
The hostile microenvironment of ischemic myocardium causes extensive cell death. Preconditioning of stem cells by short-term treatment with growth factor is shown here as a simple, safe, effective, and potentially therapeutic intervention to promote their survival after engraftment. Insulin-like growth factor-1 preconditioning also promoted connexin-43 translocation to the mitochondria. Studies are being performed to investigate a possible role for the mitochondrial connexin-43 in cytoprotection. The potential benefits of preconditioning the stem cells before transplantation are enormous and will revolutionize our thinking about strategies for cell-based therapies. See p 2587.
Improved Patient Survival Using a Modified Resuscitation Protocol for Out-of-Hospital Cardiac Arrest
This article adds to the growing body of research demonstrating the potential benefits of changes in basic resuscitation with increased emphasis on chest compressions and a deemphasis on ventilation. The study evaluated changes in an emergency medical services cardiac arrest protocol, advocating cardiopulmonary resuscitation before defibrillation for all adult out-of-hospital cardiac arrest patients, maintaining a 50:2 ratio of compressions to ventilation, restricting aggressive ventilation, and minimizing pauses for ventilation or other procedures. The rationale behind these changes was derived from the 3-phase model of cardiac arrest and based on the fact that the majority of our cardiac arrest patients are in the circulation phase of arrest when emergency medical services personnel arrive on scene. The outcome data demonstrate a nearly 2-fold increase in survival to hospital discharge of bystander-witnessed ventricular fibrillation arrest compared with a historical control treated under the 2000 emergency cardiac care guidelines. The increase in survival to hospital discharge also appears to be associated with excellent neurological outcomes. Physicians rarely rescue a cardiac arrest victim if out-of-hospital therapy has failed. Therefore, changes in the delivery of out-of-hospital resuscitation that improve survival are of great importance. Further study is required to evaluate the sustainability of these results and to investigate optimal therapy for the out-of-hospital cardiac arrest patient. See p 2597.
Mechanisms of Recurrent Functional Mitral Regurgitation After Mitral Valve Repair in Nonischemic Dilated Cardiomyopathy: Importance of Distal Anterior Leaflet Tethering
Functional mitral regurgitation (MR) is a common complication of dilated cardiomyopathy and carries a poor prognosis. Although surgical restrictive mitral annuloplasty is often performed and has been shown to improve heart failure symptoms, recurrence of MR is not uncommon and is associated with increased morbidity and mortality. We performed a study investigating the mechanisms and predictors of recurrent MR in patients with idiopathic dilated cardiomyopathy who underwent mitral annuloplasty for functional MR in the Acorn trial. We comprehensively assessed the anatomy of the mitral apparatus and the left ventricle using echocardiography before surgery and at 6 months after it. The key finding of this study is that the preoperative tethering of the distal anterior mitral leaflet as a result of left ventricular dilatation is strongly predictive of recurrence of clinically significant MR after surgery. We observed that restrictive annuloplasty exaggerates tethering of the posterior leaflet, which renders postoperative mitral valve closure almost entirely dependent on the anterior leaflet. On receiver operating characteristic curve analysis, a preoperative distal anterior leaflet tethering angle of Ͼ25°had sensitivity, specificity, and positive and negative predictive values of 88%, 94%, 82%, and 93%, respectively. Three distinct tethering patterns of the anterior leaflet (minimal, basal, and distal) in association with increasing risk of postoperative MR recurrence were described. The results of this study may be useful to clinicians for selecting candidates of mitral valve repair and developing new surgical techniques in the management of patients with functional MR. See p 2606.
